Today: 19 April 2026
Tesla Stock Falls as New Delivery Forecast Raises Fresh Demand Questions
27 March 2026
1 min read

Tesla Stock Falls as New Delivery Forecast Raises Fresh Demand Questions

NEW YORK, March 27, 2026, 12:14 PM EDT

Tesla shares slipped roughly 1.4% by midday Friday following the release of an updated analyst consensus showing weaker vehicle deliveries projected for this year. The stock traded at $366.75, having dipped to $361.67 earlier in the session.

Tesla’s latest analyst consensus shows signs that the bounce in its car business is losing steam. The company now forecasts 1.689 million car deliveries for 2026, trimmed from January’s 1.723 million figure. As car sales remain the core of today’s revenue, investors are looking even more to potential upside in AI, robotaxis, and humanoid robots.

The stock slipped in a sluggish market. The Nasdaq dropped 1.33% Friday, Reuters said, with worries over Middle East conflict and rising oil prices dragging tech stocks lower. “Words alone aren’t cutting it right now,” Hargreaves Lansdown’s Matt Britzman noted. Reuters

On Thursday, Tesla reported first-quarter deliveries at 365,645 vehicles, falling short of the 418,227 it managed in the previous quarter. Analysts pointed to energy storage deployments coming in at 14.4 gigawatt-hours for the first quarter—just edging past the prior record of 14.2 GWh.

Earlier this month, Morgan Stanley’s Adam Jonas flagged rising costs tied to autonomy, robotics, and energy as a drag on the stock. Morningstar analyst Seth Goldstein put it more bluntly: “If I look at two of the three largest markets, I’m seeing a decline,” he told Reuters. Tesla investor Gene Munster struck a different note—he figures “zero growth is a win” as long as sales don’t slip further. Reuters

Europe hasn’t given Tesla much breathing space. February registrations climbed 11.8%, breaking a year-plus decline, but BYD’s sales shot up even faster—more than doubling and landing right on Tesla’s market share. Volkswagen and Stellantis posted gains as well.

Tesla’s backdrop remains tough to overlook. The company handed over 1.64 million vehicles in 2025, slipping from 1.79 million the year before. That marks a second consecutive annual drop, and Tesla ceded the global EV sales crown to BYD.

Tesla has been working to redirect investor attention. Back in January, the company announced a $2 billion investment in Elon Musk’s xAI, and stuck to its plans for Cybercab production this year, all while Chief Financial Officer Vaibhav Taneja flagged that spending on factories and equipment is set to push past $20 billion. For Thomas Monteiro at Investing.com, the main thing to watch now isn’t deliveries.

Still, Tesla makes clear it doesn’t back the analyst estimates it posts; the consensus figure is just a reference point, not company guidance. A shortfall in first-quarter deliveries—even versus that muted expectation—would leave investors sizing up a car-centric operation against a pricier wager on software and robotics that hasn’t paid off in cash flows yet.

Stock Market Today

  • Align Technology (ALGN) Valuation Update After Recent Share Price Rise
    April 18, 2026, 11:43 PM EDT. Align Technology (ALGN) shares have rebounded roughly 9.8% over the past month, trading near $190. Despite a 21.8% gain year-to-date, the stock is down 46.5% over three years, reflecting mixed long-term performance. Simply Wall St's valuation checks score ALGN 1 out of 6, signaling caution. A Discounted Cash Flow (DCF) model estimates fair value at $205.48, suggesting shares are about 7.5% undervalued-indicating current prices are close to intrinsic value rather than clearly cheap or expensive. The stock's price-to-earnings (P/E) ratio stands at 33.17, above the sector average, reflecting expectations of growth and risk. Investors should weigh recent momentum against historic declines and monitor valuations closely for shifts.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Unity Software Stock Price Surges 11% After Q1 Revenue Beat, Ad Exit Plan
Previous Story

Unity Software Stock Price Surges 11% After Q1 Revenue Beat, Ad Exit Plan

Dow Jones Industrial Average Today: DJIA Falls as Oil Tops $110 and Fed Cut Hopes Fade
Next Story

Dow Jones Industrial Average Today: DJIA Falls as Oil Tops $110 and Fed Cut Hopes Fade

Go toTop